Precigen reported strong sequential growth in sales of PAPZIMEOS, its treatment for adults with recurrent respiratory papillomatosis (RRP), and said it generated positive cash flow in the third quarter—one quarter earlier than its guidance had anticipated. The company also highlighted a new FDA designation for its AdenoVerse platform and longer-term data showing durable responses after PAPZIMEOS treatment.
Key details
-
PAPZIMEOS revenue rose 37% from the prior quarter to $72.9 million. Launch-to-date net product revenue reached $151 million through September 30, 2026.
-
Precigen said it achieved positive cash flow in the quarter ahead of guidance. It also reported net income of $35.8 million. Cash, cash equivalents and investments totaled $51.0 million at quarter-end.
-
More than 500 patients had begun PAPZIMEOS treatment as of November 4, and more than 300 had completed treatment, according to the company. Precigen said the treatment is gaining adoption as a first-line option for adults with RRP.
-
The company cited a 51% complete response rate in describing the treatment’s clinical profile. Longer-term follow-up data presented at the 2026 AAO-HNSF meeting showed ongoing durable complete responses in some patients for up to five years after treatment.
-
The FDA granted Platform Technology Designation to Precigen’s AdenoVerse platform in September. Precigen said the designation creates opportunities to expedite development of therapies using the platform; it is not an approval of a particular medicine.
-
Precigen is pursuing additional development and commercial opportunities for PAPZIMEOS, including a clinical trial evaluating redosing, pediatric development and geographic expansion. The company also said PAPZIMEOS received full FDA approval without a confirmatory trial.
Plain-English implications
PAPZIMEOS is now generating substantial product revenue, and Precigen says the resulting cash flow arrived earlier than expected. The FDA’s platform designation applies to AdenoVerse, the technology platform, while the redosing, pediatric and geographic-expansion efforts are separate parts of the company’s plans to broaden PAPZIMEOS’s reach.